Molecular Target Identification: Proprietary Technology Platform

Capture compound® mass spectrometry (CCMS) target identification technology facilitates the target deconvolution identification, optimization, and development to market of bioactive small molecules and the development of protein biomarkers, thus reducing risk and cost for our clients. CCMS, a proprietary technology of Charles River, proprietary protein capture technology for phenotypic screening target deconvolution.

Capture compound mass spectrometry (CCMS) is based on:

  • Trifunctional molecules – Capture Compounds
  • Chemistry know-how for tailored design
  • Proprietary workflow
  • No solid matrix, in solution application
  • Specificity controls
  • Covalent crosslinking for high sensitivity

CCMS delivers a ranked short list of specific protein interactors for any small molecule. Watch the video to learn more.

BENEFITS & APPLICATIONS
  • Compound Profiling for Phenotypic Drug Discovery

    CCMS-mediated target identification (ID) provides:

    • Identified targets for phenotypic compound-finding campaigns
    • ID of binding site and mode of interaction
    • Targets in any cellular compartment (e.g., GPCRs, ion channels, cytoplasmic signaling proteins and enzymes, nuclear proteins)
    • Proteins of low abundance
    • Molecular target identification for mechanism of action, adverse events, or toxicities in any tissue or species
    • Novel mechanistic targets for compound re-positioning

    Capture Compound Mass Spectrometry diagram

  • Chemistry Decision Making for Target Validation

    Target deconvolution by CCMS profiling enables:

    • Prediction of human toxicity liability
    • Guidance of lead optimization and regulatory programs to help you choose the best development candidate
    • Replacement of assay development and screening
    • Avoidance of unexpected events in later development
    • Data-driven decision-making for crucial milestones
  • Managing Risk in Drug Target Proteomics

    CCMS risk-prediction offers to collaborators:

    • Information-based decision making
    • Cross species comparisons
    • Tissue comparisons
    • Toxicity predictions
    • Compound-specific biomarkers
    • Personalized therapeutics
    • Better candidate selection
    • Development path design
  • Target Engagement Assay Services

    CCMS profiling supports projects across discovery & development delivering:

    • Molecular target identification from phenotypic screens
    • Drug discovery support
    • Biomarkers for personalization and product rescue
    • Product positioning
    • Compound re-purposing
    • Life cycle management support